

APR 25 2003

RECEIVED
APR 30 2003
TECH CENTER 1600/2900

EXPRESS MAIL NO.: EL 401 281 008 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Herman et al.	Confirmation No.:	7952
Serial No.:	10 033,662	Art Unit:	1614
Filed:	December 27, 2001	Examiner:	To be assigned
For:	PROTEINS, GENES AND THEIR USE FOR DIAGNOSIS AND TREATMENT OF CARDIAC RESPONSE	Attorney Docket No.	9195-081-999

#17
Plunkett
5/29/03

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the Patent Office of all references coming to the attention of Applicants or their attorneys which are or may be related to patentability of the claimed invention, Applicants hereby direct the Examiner's attention to references AA-AU listed on the accompanying revised PTO Form 1449. A copy of references AA-AU is submitted herewith.


Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the above-identified patent application.

Pursuant to 37 CFR §1.97(b), since this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits, it is believed that no fee is due in connection herewith. However, should the Patent and Trademark Office determine

otherwise, please charge the required fee to Pennie & Edmonds LLP Deposit Account No.
16-1150.


Respectfully submitted,

Date: April 25, 2003



Laura A. Coruzzi 30,742
(Reg. No.)

By:



Scott A. Warren 47,167
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036
(212) 790-9090

Enclosures

RECEIVED

Sheet 1 of 2

APR 25 2003

APR 3

ATTY DOCKET NO.

APPLICATION NO.

9195-081-999

10 033,662

LIST OF REFERENCES RECEIVED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Herman et al.

FILING DATE

December 27, 2001

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
AA	WO 99 47925	9 23 99	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AB	Arrell et al. Cardiovascular proteomics: evolution and potential. Circ Res. 2001 Apr 27;88(8):763-73. Review
AC	Booth et al. A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation. 1995 Feb 15;91(4):962-7
AD	Collinson et al. Measurement of cardiac troponins. Ann Clin Biochem. 2001 Sep;38(Pt 5):423-49. Review
AE	Heinke et al. Changes in myocardial protein expression in pacing-induced canine heart failure. Electrophoresis. 1999 Jul;20(10):2086-93
AF	Herman et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol. 1999 Jul;17(7):2237-43
AG	Herman et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol. 2001 Oct;48(4):297-304
AH	Herman et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 1998 Jan 15;58(2):195-7
AI	Hesse et al. Cardiac amyloidosis: a review and report of a new transthyretin (prealbumin) variant. Br Heart J. 1993 Aug;70(2):111-5. Review
AJ	Labugger et al. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation. 2000 Sep 12;102(11):1221-6
AK	Li et al. A two-dimensional electrophoresis database of rat heart proteins. Electrophoresis. 1999 Apr-May;20(4-5):891-7
AL	Macri et al. Application of proteomics to the study of cardiovascular biology. Trends Cardiovasc Med. 2001 Feb;11(2):66-75. Review
AM	Malik et al. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf. 2001;24(5):323-51. Review
AN	Manabe et al. A nondenaturing protein map of human plasma proteins correlated with a denaturing polypeptide map combining techniques of micro two-dimensional gel electrophoresis. Electrophoresis. 1999 Apr-May;20(4-5):830-5
AO	Morandi et al. Serum cardiac troponin I levels and ECG Echo monitoring in breast cancer patients undergoing high-dose (7 g m(2)) cyclophosphamide. Bone Marrow Transplant. 2001 Aug;28(3):277-82
AP	Oza et al. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg Med Chem Lett. 1999 Jan 4;9(1):1-6
AQ	Page et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mamoplasties. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12589-94

NY2 1419641

APR 2 5 2003

AR

Pai et al. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000 Apr;22(4):263-302. Review

AS

Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med. 1999 Jun 1;130(11):933-7. Review

AT

Sironi et al. Acute-phase proteins before cerebral ischemia in stroke-prone rats: identification by proteomics. Stroke. 2001 Mar;32(3):753-60.

AU

Wojtacki et al. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature. Med Sci Monit. 2000 Mar-Apr;6(2):411-20. Review

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

APR 3 0 2003

TECH CENTER 1600.25